At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 39 enrolled
Drug / intervention
Padsevonildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants
In Brief
A Phase 1 clinical trial evaluating Padsevonil for Healthy Japanese Participants. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The purpose of the study is to investigate the pharmacokinetics (PK) of padesevonil in CYP2C19 genotyped healthy male Japanese study participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Japanese Participants
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartSep 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedAug 30, 2019
Enrollment StartSep 30, 2019
Primary CompletionDec 27, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.8 years ago
Interventions
Padsevonildrug
Padsevonil will be administered in predefined dosages.